← Back to Search

CAR T-cell Therapy

TBX-3400 for Cancer

Phase 1 & 2

Waitlist Available

Research Sponsored by Taiga Biotechnologies, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 8 months

Awards & highlights

Study Summary

This trial is studying a gene-modified cell therapy called TBX-3400 in people with cancer that has not responded to standard therapy. In this therapy, a person's own blood cells are exposed to a protein that has been shown to kill cancer cells in the laboratory. The study hypothesis is that TBX-3400 cells will help the body's immune system to better fight the cancer.

Eligible Conditions

Refractory Cancer
Cancer
Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 8 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~8 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

The primary endpoint is the incidence and severity of treatment-emergent adverse events (TEAEs), including the incidence of dose-limiting toxicities (DLTs), graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Secondary outcome measures

Assessment of concentrations of certain proteins such as cluster of differentiation 69 (CD69), as biomarkers of activity of TBX-3400

Presence and/or concentration of anti TBX-3400 antibodies

Tumor Responses as defined by RECIST

Other outcome measures

Quantification of the concentration of interferon-alpha (IFN-α) in plasma

Quantification of the concentration of interferon-gamma (IFN-γ) in plasma

Quantification of the concentration of interferon-gamma inducible protein 10kD (IP-10) in plasma

+3 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: TBX-3400Experimental Treatment1 Intervention

TBX-3400 by intravenous infusion

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Taiga Biotechnologies, Inc.Lead Sponsor

3 Previous Clinical Trials

90 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are currently engaged in this experiment?

"Affirmative. According to the information on clinicaltrials.gov, this medical study is currently recruiting patients with a first post date of January 25th 2021 and an updated version posted February 1st 2022. At present, 60 participants are needed for evaluation at one location."

Answered by AI

Are there any unfilled slots in this trial for potential participants?

"The trial, which was initially posted on January 25th 2021 and updated on February 1st 2022, is actively seeking participants. This information can be found in the database hosted by clinicaltrials.gov."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

2021. "Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04640246.